Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna GlobeNewswire - Mon Mar 3, 8:15AM CST

ABUS : 3.20 (-2.44%)
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO GlobeNewswire - Tue Feb 25, 6:00AM CST

ABUS : 3.20 (-2.44%)
Arbutus Provides 2025 Corporate and Financial Update GlobeNewswire - Mon Jan 13, 6:30AM CST

ABUS : 3.20 (-2.44%)
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat GlobeNewswire - Tue Nov 26, 2024

ABUS : 3.20 (-2.44%)
Arbutus Biopharma Reports 50% Functional Cure Rate in Phase 2a Clinical Trial for Chronic Hepatitis B Virus Quiver Quantitative, Inc. - Fri Nov 15, 2024

Arbutus Biopharma reports 50% functional cure rate in HBeAg-negative patients with low HBsAg after IM-PROVE I trial.Quiver AI SummaryArbutus Biopharma Corporation announced promising results from its IM-PROVE...

ABUS : 3.20 (-2.44%)
Arbutus Biopharma and Barinthus Bio Report Encouraging Preliminary Results from Phase 2a IM-PROVE II Clinical Trial for Chronic Hepatitis B Virus Quiver Quantitative, Inc. - Fri Nov 15, 2024

Imdusiran, VTP-300, and low-dose nivolumab demonstrated significant HBsAg reduction in a Phase 2a clinical trial for chronic hepatitis B.Quiver AI SummaryArbutus Biopharma and Barinthus Biotherapeutics...

ABUS : 3.20 (-2.44%)
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon GlobeNewswire - Fri Nov 15, 2024

ABUS : 3.20 (-2.44%)
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B GlobeNewswire - Fri Nov 15, 2024

ABUS : 3.20 (-2.44%)
Arbutus to Present at Jefferies London Healthcare Conference GlobeNewswire - Thu Nov 14, 2024

ABUS : 3.20 (-2.44%)
Arbutus: Q3 Earnings Snapshot AP - Wed Nov 6, 2024

Arbutus: Q3 Earnings Snapshot

ABUS : 3.20 (-2.44%)

Barchart Exclusives

Stock Index Futures Gain With All Eyes on Fed Rate Decision Barchart - 25 minutes ago
March S&P 500 E-Mini futures (ESH25) are up +0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.22% this morning, pointing to a slightly higher open on Wall Street as investors await the Federal Reserve’s policy decision and Chair Jerome Powell’s comments. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot